Clinical trial
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Assess Aesthetic Improvement and Onset of QM1114-DP Treatment Effect in Subjects With Moderate to Severe Glabellar Lines
NCT05146999 is registered in ClinicalTrials.gov with Galderma R&D as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Assess Aesthetic Improvement and Onset of QM1114-DP Treatment Effect in Subjects With Moderate to Severe Glabellar Lines
- Lead sponsor
- Galderma R&D
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 9, 2022
- Completion date
- September 1, 2023
- Enrollment
- 132 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
glabellar frown lines